| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |